you are viewing a single comment's thread.
They have the worst patent-cliff situation in big, domestic pharma. They are in process of losing Zyprexa and Gemzar - and Cymbalta expiry isn't far off either. LLY hasn't made acquisitions which would enable them to really cut costs, their dividend payount is too great and they don't buy back shares or slash R & D. What's to like?
I find it very telling you can not understand what you read. That fact goes a long way in explaining your poor performance over the long term.